Premium Nahrungsergänzungsmittel | artgerecht

Immune Cell Transfer – Definition and Therapy

Immune cell transfer is a medical procedure in which immune cells are taken from a donor or patient and infused into a recipient to treat cancer or immune disorders.

Regular tips about health Regular tips about health

Things worth knowing about "Immune Cell Transfer"

Immune cell transfer is a medical procedure in which immune cells are taken from a donor or patient and infused into a recipient to treat cancer or immune disorders.

What is Immune Cell Transfer?

Immune cell transfer – also known as adoptive cell transfer (ACT) – is a therapeutic approach in which immune cells are collected from a patient or a healthy donor, processed or genetically engineered in a laboratory, and then infused back into the patient. The goal is to enhance or redirect the immune response to fight diseases such as cancer, chronic viral infections, or certain immune disorders. This method is a cornerstone of modern immunotherapy and represents one of the most active areas of personalized medicine research.

Types of Immune Cell Transfer

Autologous Cell Transfer

In autologous immune cell transfer, the patient's own immune cells are harvested, expanded, activated, or genetically modified in a laboratory before being reinfused. The most well-known example is CAR-T cell therapy, in which T lymphocytes are engineered to express a chimeric antigen receptor (CAR) that enables them to specifically recognize and destroy tumor cells.

Allogeneic Cell Transfer

In allogeneic immune cell transfer, immune cells are obtained from a healthy matched donor. This approach is commonly used in the context of stem cell transplantation and takes advantage of the graft-versus-leukemia (GvL) effect, where donor immune cells recognize and eliminate residual cancer cells in the recipient.

Mechanism of Action

Immune cell transfer exploits the natural ability of immune cells – particularly T cells, natural killer (NK) cells, and dendritic cells – to identify and eliminate pathogens or abnormal cells. By selecting, activating, or genetically modifying these cells outside the body, their therapeutic potency is significantly enhanced. Once reinfused, these cells seek out their target structures and mount a directed immune response against them.

Clinical Applications

Oncology: Treatment of leukemias, lymphomas, and solid tumors (e.g., via CAR-T cell therapy)
Infectious diseases: Management of chronic viral infections such as HIV or cytomegalovirus (CMV) reactivation after transplantation
Autoimmune conditions: Experimental use to modulate dysregulated immune responses
Stem cell transplantation: Donor T cell infusions to combat residual leukemia after allogeneic transplant

Benefits and Opportunities

Compared to conventional treatments such as chemotherapy or radiation, immune cell transfer offers the advantage of a highly targeted mechanism of action with potentially fewer off-target effects on healthy tissue. In certain cancers refractory to standard therapies, CAR-T cell-based approaches have achieved remarkable and durable remissions.

Risks and Side Effects

Despite promising results, immune cell transfer is associated with notable risks. These include:

Cytokine release syndrome (CRS): A potentially life-threatening systemic inflammatory response triggered by massive immune activation
Graft-versus-host disease (GvHD): In allogeneic transfers, donor cells may attack the recipient's healthy tissues
Neurotoxicity: Neurological side effects observed particularly with CAR-T cell therapies
Infection risk: Due to temporary immunosuppression used to prepare the patient before therapy

Current Developments and Outlook

Research in immune cell transfer is advancing rapidly. In addition to CAR-T cells, TCR-engineered T cells (with modified T cell receptors) and NK cell-based therapies are being intensively investigated. Researchers aim to make these therapies safer, more effective, and more widely accessible – including for patients with solid tumors, where current CAR-T approaches show limited efficacy. There is also growing interest in off-the-shelf cell products derived from donor material, which could be manufactured in advance and deployed quickly and cost-effectively.

References

Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-68.
June CH, Sadelain M. Chimeric Antigen Receptor Therapy. New England Journal of Medicine. 2018;379(1):64-73.
National Cancer Institute (NCI). CAR T Cells: Engineering Immune Cells to Treat Cancer. Available at: https://www.cancer.gov. Accessed 2024.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.